Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial
Mehdi Hamadani(Medical College of Wisconsin), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Paolo F. Caimi(University Hospitals Seidman Cancer Center), Zhiying Cindy Xu, Brian Hess(Washington University in St. Louis), Carmelo Carlo‐Stella(Humanitas University), Alexander I. Spira(Virginia Cancer Specialists), Xiaolei Zhou(Guangxi Medicinal Botanical Garden), Anastasios Stathis(Princess Margaret Cancer Centre), Weiyun Z. Ai(City College of San Francisco), Kirit M. Ardeshna(UCL Biomedical Research Centre), Brad S. Kahl(UW Health University Hospital), Juan Pablo Alderuccio(Sylvester Comprehensive Cancer Center), Lei Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Ying Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yajuan Qin, Melhem Solh(Johns Hopkins Hospital), Laura Liao(Providence College), John Radford(Manchester Academic Health Science Centre)
Cited by 7
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k